Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients

Retrovirology

Volumn 5, Issue , 2008, Pages

  Kapoor, Amit ^a,b   Shapiro, Beth ^c   Shafer, Robert W ^d   Shulman, Nancy ^d   Rhee, Soo Yon ^d   Delwart, Eric L ^a,b  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; INDINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SALVAGE THERAPY; VIRUS DETECTION; VIRUS GENOME; VIRUS MUTATION; DRUG EFFECT; EVOLUTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; TREATMENT FAILURE; VIROLOGY;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; EVOLUTION; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOME, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 40549137769     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-5-7     Document Type: Article

References (38)

1. Coffin JM HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy Science 1995, 267:483-489. 10.1126/ science.7824947 7824947
2. Paolucci S Baldanti F Campanini G Zavattoni M Cattaneo E Dossena L Gerna G Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients J Med Virol 2001, 65:207-217. 10.1002/jmv.2022 11536225
3. Kepler TB Perelson AS Drug concentration heterogeneity facilitates the evolution of drug resistance Proc Natl Acad Sci USA 1998, 95:11514-11519. 21672 9751697 10.1073/pnas.95.20.11514
4. Magierowska M Bernardin F Garg S Staprans S Miller MD Van Rompay KK Delwart EL Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques J Virol 2004, 78:2434-2444. 369237 14963139 10.1128/ JVI.78.5.2434-2444.2004
5. Molla A Korneyeva M Gao Q Vasavanonda S Schipper PJ Mo HM Markowitz M Chernyavskiy T Niu P Lyons N Ordered accumulation of mutations in HIV protease confers resistance to ritonavir Nat Med 1996, 2:760-766. 10.1038/nm0796-760 8673921
6. Shafer RW Genotypic testing for human immunodeficiency virus type 1 drug resistance Clin Microbiol Rev 2002, 15:247-277. 118066 11932232 10.1128/ CMR.15.2.247-277.2002
7. Condra JH Holder DJ Schleif WA Blahy OM Danovich RM Gabryelski LJ Graham DJ Laird D Quintero JC Rhodes A Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor J Virol 1996, 70:8270-8276. 190914 8970946
8. Condra JH Schleif WA Blahy OM Gabryelski LJ Graham DJ Quintero JC Rhodes A Robbins HL Roth E Shivaprakash M In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors [see comments] Nature 1995, 374:569-571. 10.1038/374569a0 7700387
9. Kijak GH Simon V Balfe P Vanderhoeven J Pampuro SE Zala C Ochoa C Cahn P Markowitz M Salomon H Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure J Virol 2002, 76:7000-7009. 136319 12072500 10.1128/JVI.76.14.7000-7009.2002
10. Nijhuis M Schuurman R de Jong D Erickson J Gustchina E Albert J Schipper P Gulnik S Boucher CA Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy Aids 1999, 13:2349-2359. 10.1097/00002030-199912030-00006 10597776
11. Mammano F Petit C Clavel F Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients J Virol 1998, 72:7632-7637. 110025 9696866
12. Gatanaga H Suzuki Y Tsang H Yoshimura K Kavlick MF Nagashima K Gorelick RJ Mardy S Tang C Summers MF Mitsuya H Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors J Biol Chem 2002, 277:5952-5961. 10.1074/jbc.M108005200 11741936
13. Cote HC Brumme ZL Harrigan PR Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir J Virol 2001, 75:589-594. 113954 11134271 10.1128/JVI.75.2.589-594.2001
14. Nijhuis M Boucher CA Schipper P Leitner T Schuurman R Albert J Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy Proc Natl Acad Sci USA 1998, 95:14441-14446. 24392 9826719 10.1073/pnas.95.24.14441
15. Coffin JM HIV viral dynamics Aids 1996, 10(Suppl 3):S75-84. 8970715
16. Barrie KA Perez EE Lamers SL Farmerie WG Dunn BM Sleasman JW Goodenow MM Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1 Virology 1996, 219:407-416. 10.1006/ viro.1996.0266 8638406
17. Croteau G Doyon L Thibeault D McKercher G Pilote L Lamarre D Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors J Virol 1997, 71:1089-1096. 191160 8995629
18. Barbour JD Wrin T Grant RM Martin JN Segal MR Petropoulos CJ Deeks SG Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults J Virol 2002, 76:11104-11112. 136622 12368352 10.1128/JVI.76.21.11104-11112.2002
19. Borman AM Paulous S Clavel F Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug J Gen Virol 1996, 77(Pt 3):419-426. 8601776
20. Condra JH Schleif WA Blahy OM Gabryelski LJ Graham DJ Quintero JC Rhodes A Robbins HL Roth E Shivaprakash M In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature 1995, 374:569-571. 10.1038/374569a0 7700387
21. Deeks SG Wrin T Liegler T Hoh R Hayden M Barbour JD Hellmann NS Petropoulos CJ McCune JM Hellerstein MK Grant RM Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia N Engl J Med 2001, 344:472-480. 10.1056/NEJM200102153440702 11172188
22. Doukhan L Delwart E Population genetic analysis of the protease locus of human immunodeficiency virus type 1 quasispecies undergoing drug selection, using a denaturing gradient-heteroduplex tracking assay J Virol 2001, 75:6729-6736. 114399 11413343 10.1128/ JVI.75.14.6729-6736.2001
23. Gandhi RT Wurcel A Rosenberg ES Johnston MN Hellmann N Bates M Hirsch MS Walker BD Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus Clin Infect Dis 2003, 37:1693-1698. 10.1086/379773 14689353
24. Charpentier C Dwyer DE Mammano F Lecossier D Clavel F Hance AJ Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors J Virol 2004, 78:4234-4247. 374292 15047838 10.1128/JVI.78.8.4234-4247.2004
25. Nora T Charpentier C Tenaillon O Hoede C Clavel F Hance AJ Contribution of Recombination to the Evolution of Human Immunodeficiency Viruses Expressing Resistance to Antiretroviral Treatment J Virol 2007, 1933369 17494080
26. Charpentier C Nora T Tenaillon O Clavel F Hance AJ Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients J Virol 2006, 80:2472-2482. 1395372 16474154 10.1128/ JVI.80.5.2472-2482.2006
27. Hong L Zhang XC Hartsuck JA Tang J Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance Protein Sci 2000, 9:1898-1904. 2144469 11106162
28. Ode H Ota M Neya S Hata M Sugiura W Hoshino T Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases J Phys Chem B 2005, 109:565-574. 10.1021/jp046860+ 16851048
29. Ode H Neya S Hata M Sugiura W Hoshino T Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M J Am Chem Soc 2006, 128:7887-7895. 10.1021/ja060682b 16771502
30. Bally F Martinez R Peters S Sudre P Telenti A Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors AIDS Res Hum Retroviruses 2000, 16:1209-1213. 10.1089/08892220050116970 10957718
31. Bruen TC Philippe H Bryant D A simple and robust statistical test for detecting the presence of recombination Genetics 2006, 172:2665-2681. 1456386 16489234 10.1534/genetics.105.048975
32. Huson DH Bryant D Application of phylogenetic networks in evolutionary studies Mol Biol Evol 2006, 23:254-267. 10.1093/molbev/msj030 16221896
33. Watkins T Resch W Irlbeck D Swanstrom R Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors Antimicrob Agents Chemother 2003, 47:759-769. 151730 12543689 10.1128/ AAC.47.2.759-769.2003
34. Feher A Weber IT Bagossi P Boross P Mahalingam B Louis JM Copeland TD Torshin IY Harrison RW Tozser J Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites Eur J Biochem 2002, 269:4114-4120. 10.1046/j.1432-1033.2002.03105.x 12180988
35. Jung A Maier R Vartanian JP Bocharov G Jung V Fischer U Meese E Wain-Hobson S Meyerhans A Multiply infected spleen cells in HIV patients Nature 2002, 418:144. 10.1038/418144a 12110879
36. Metzner KJ Allers K Rauch P Harrer T Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients Aids 2007, 21:703-711. 10.1097/QAD.0b013e3280121ac6 17413691
37. Bayesian Evolutionary Analysis Sampling Trees http://beast.bio.ed.ac.uk
38. Drummond AJ Ho SY Phillips MJ Rambaut A Relaxed phylogenetics and dating with confidence PLoS Biol 2006, 4:e88. 1395354 16683862 10.1371/ journal.pbio.0040088